Pacific Biosciences of California Dirección

Dirección controles de criterios 2/4

El CEO de Pacific Biosciences of California's es Christian O. Henry , nombrado en Sep 2020, tiene una permanencia de 3.58 años. compensación anual total es $6.62M, compuesta por 10.1% salario y 89.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.11% de las acciones de la empresa, por valor de €385.79K. La antigüedad media del equipo directivo y de la junta directiva es de 3.4 años y 11.2 años, respectivamente.

Información clave

Christian O. Henry

Chief Executive Officer (CEO)

US$8.0m

Compensación total

Porcentaje del salario del CEO	8.6%
Permanencia del CEO	3.7yrs
Participación del CEO	0.1%
Permanencia media de la dirección	3.3yrs
Promedio de permanencia en la Junta Directiva	11.3yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Christian O. Henry en comparación con los beneficios de Pacific Biosciences of California?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$297m
Dec 31 2023	US$8m	US$695k	-US$307m
Sep 30 2023	n/a	n/a	-US$309m
Jun 30 2023	n/a	n/a	-US$319m
Mar 31 2023	n/a	n/a	-US$321m
Dec 31 2022	US$7m	US$667k	-US$314m
Sep 30 2022	n/a	n/a	-US$299m
Jun 30 2022	n/a	n/a	-US$206m
Mar 31 2022	n/a	n/a	-US$175m
Dec 31 2021	US$3m	US$650k	-US$181m
Sep 30 2021	n/a	n/a	-US$37m
Jun 30 2021	n/a	n/a	-US$77m
Mar 31 2021	n/a	n/a	-US$59m
Dec 31 2020	US$13m	US$195k	US$29m
Sep 30 2020	n/a	n/a	-US$46m
Jun 30 2020	n/a	n/a	-US$51m
Mar 31 2020	n/a	n/a	-US$53m
Dec 31 2019	US$100k	n/a	-US$84m
Sep 30 2019	n/a	n/a	-US$115m
Jun 30 2019	n/a	n/a	-US$111m
Mar 31 2019	n/a	n/a	-US$109m
Dec 31 2018	US$88k	n/a	-US$103m

Compensación vs. Mercado: La compensación total de Christian O.($USD6.62M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD1.02M).

Compensación vs. Ingresos: La compensación de Christian O. ha aumentado mientras la empresa no es rentable.

CEO

Christian O. Henry (55 yo)

3.7yrs

Permanencia

US$8,046,575

Compensación

Mr. Christian O. Henry, MBA, served as Independent Director at CM Life Sciences III Inc. since April 07, 2021 until December 2021. He has been President and Chief Executive Officer at Pacific Biosciences o...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Christian O. Henry	President	3.7yrs	US$8.05m	0.11% $ 516.9k
Susan Kim	Chief Financial Officer	3.7yrs	US$2.52m	0.036% $ 167.8k
Mark Van Oene	Chief Operating Officer	3.3yrs	US$4.60m	0.10% $ 481.5k
Jeff Eidel	Chief Commercial Officer	1.8yrs	US$2.53m	0.032% $ 150.0k
Stephen Turner	Co-Founder	23.8yrs	US$466.76k	sin datos
Michele Farmer	VP & Chief Accounting Officer	3yrs	sin datos	0.013% $ 62.4k
Trevin Rard	Head of Investor Relations	no data	sin datos	sin datos
Brett Atkins	General Counsel & Corporate Secretary	no data	sin datos	sin datos
Natalie Welch	Chief People Officer	no data	sin datos	sin datos
Denis Zaccarin	Senior Vice President of Research & Development	1.1yrs	US$1.48m	sin datos
Mike Goloubef	Senior Vice President of Manufacturing & Quality	no data	sin datos	sin datos

3.3yrs

Permanencia media

50yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de P09 se considera experimentado (3.4 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Christian O. Henry	President	5.8yrs	US$8.05m	0.11% $ 516.9k
William Ericson	Independent Director	20.3yrs	US$259.00k	0.0069% $ 32.4k
Lucy Shapiro	Independent Director	11.7yrs	US$255.00k	0% $ 0
John Milligan	Independent Chairman	10.8yrs	US$297.00k	0.040% $ 189.6k
Harry Gray	Member of the Scientific Advisory Board	no data	sin datos	sin datos
Joseph Bonventre	Member of the Scientific Advisory Board	no data	sin datos	sin datos
Randall Livingston	Independent Director	15.3yrs	US$265.00k	0% $ 0
Harold Craighead	Member of the Scientific Advisory Board	no data	sin datos	sin datos
Roger Kornberg	Member of the Scientific Advisory Board	no data	sin datos	sin datos
Watt Webb	Member of the Scientific Advisory Board	no data	sin datos	sin datos
Kenneth Johnson	Member of the Scientific Advisory Board	no data	sin datos	sin datos
Jay Shendure	Chairman of Scientific Advisory Board	1.5yrs	sin datos	sin datos

11.3yrs

Permanencia media

69yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de P09 son experimentados ( 11.2 años antigüedad media).

Pacific Biosciences of California Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Pacific Biosciences of California, Inc., Annual General Meeting, Jun 18, 2024

Insider recently bought €162k worth of stock

President recently sold €445k worth of stock

Chief Operating Officer recently sold €221k worth of stock

Pacific Biosciences of California, Inc. Announces Resignation of David Botstein from the Board

Pacific Biosciences of California, Inc. Appoints David Meline to Audit Committee

Recent updates

First quarter 2024 earnings released: US$0.29 loss per share (vs US$0.36 loss in 1Q 2023)

Pacific Biosciences of California, Inc., Annual General Meeting, Jun 18, 2024

Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2024

PacBio Announces PureTarget Repeat Expansion Panel, Expanding Its Portfolio of End-To-End Clinical Research Solutions

Insider recently bought €162k worth of stock

Full year 2023 earnings released: US$1.21 loss per share (vs US$1.40 loss in FY 2022)

President recently sold €445k worth of stock

Full year 2023 earnings released: US$1.21 loss per share (vs US$1.40 loss in FY 2022)

Pacific Biosciences of California, Inc Announces HiFi Prep Kit 96 and HiFi Plex Prep Kit 96 for Long-Read Sequencing Applications at Scale

Pacific Biosciences of California, Inc. to Report Q4, 2023 Results on Feb 15, 2024

PacBio Announces New Nanobind Pandna Kit Enabling Hifi Optimized Dna Extraction Solutions

Chief Operating Officer recently sold €221k worth of stock

Pacific Biosciences of California, Inc. Announces Resignation of David Botstein from the Board

PacBio Announces HiFi Solves, a Global Consortium of Clinical Genomics Research Leaders

Third quarter 2023 earnings released: US$0.26 loss per share (vs US$0.34 loss in 3Q 2022)

Pacific Biosciences of California, Inc. Appoints David Meline to Audit Committee

Pacific Biosciences of California, Inc. Appoints David Meline to its Board of Directors

Pacific Biosciences of California, Inc. to Report Q3, 2023 Results on Oct 30, 2023

Pacbio Announces Complete Computational Workflow for Human Whole Genome Sequencing Data Analysis

President recently sold €918k worth of stock

Chief Operating Officer recently sold €263k worth of stock

Pacific Biosciences of California, Inc. (NasdaqGS:PACB) entered into an agreement to acquire Apton Biosystems, Inc. for approximately $110 million.

Second quarter 2023 earnings released: US$0.28 loss per share (vs US$0.32 loss in 2Q 2022)

Pacific Biosciences of California, Inc. (NasdaqGS:PACB) entered into an agreement to acquire Apton Biosystems, Inc. for $110 million.

Pacific Biosciences of California, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Now 25% undervalued

Pacific Biosciences of California, Inc. Announces Board Changes

VP & Chief Accounting Officer recently sold €60k worth of stock

Insufficient new directors

Full year 2022 earnings released: US$1.40 loss per share (vs US$0.89 loss in FY 2021)

PacBio to Expand MAS-Seq Technology to 16S rRNA and Bulk RNA-Seq Solutions

Pacific Biosciences of California, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Insufficient new directors

Pacific Biosciences of California, Inc. has completed a Follow-on Equity Offering in the amount of $175 million.

Pacific Biosciences of California, Inc. has completed a Follow-on Equity Offering in the amount of $175 million.

Pacific Biosciences of California, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2022

Pacific Biosciences of California, Inc. Announces Board Appointments

Pacific Biosciences of California, Inc. Withdraws its Financial Guidance

Pacific Biosciences of California, Inc. to Report Q3, 2022 Results on Nov 07, 2022

PacBio Launches Single-Cell Transcriptome Solution Ushering in a New Era of RNA Discovery

PacBio and Twist Bioscience Deliver Initial Portfolio of Target Enrichment Panels for HiFi Sequencing

Chief Financial Officer recently sold €75k worth of stock

PacBio Unveils A New Method for Comprehensive, Genome-Wide Tandem Repeat Analysis

Second quarter 2022 earnings released: US$0.32 loss per share (vs US$0.21 loss in 2Q 2021)

Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Full Year 2022

Pacific Biosciences of California, Inc. Appoints Jeff Eidel as Chief Commercial Officer, Effective August 16, 2022

Pacific Biosciences of California, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Pacific Biosciences of California, Inc. Announces Management Changes

First quarter 2022 earnings released: US$0.37 loss per share (vs US$0.45 loss in 1Q 2021)

Insufficient new directors

Pacific Biosciences of California, Inc. to Report Q1, 2022 Results on May 04, 2022

Pacific Biosciences of California, Inc., Annual General Meeting, May 25, 2022

Insufficient new directors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Pacific Biosciences of California, Inc. to Report Q4, 2021 Results on Feb 15, 2022

Chief Operating Officer recently sold €519k worth of stock

Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Fourth Quarter and the Fiscal Year Ended December 31, 2021

PacBio’s New HiFiViral Surveillance Kit Performance is Not Impacted by Omicron Mutations, Delivering Complete SARS-CoV-2 Genomes for All Circulating Variants

Insufficient new directors

Third quarter 2021 earnings released: EPS US$0.082 (vs US$0.14 loss in 3Q 2020)

Pacific Biosciences of California, Inc. (NasdaqGS:PACB) completed the acquisition of Omniome, Inc.

Pacific Biosciences of California, Inc. (NasdaqGS:PACB) acquired Circulomics, Inc.

Second quarter 2021 earnings released: US$0.21 loss per share (vs US$0.15 loss in 2Q 2020)

Senior Fellow & Director Michael Hunkapiller has left the company

VP & Chief Accounting Officer has left the company

First quarter 2021 earnings released: US$0.45 loss per share (vs US$0.008 profit in 1Q 2020)

Pacific Biosciences of California, Inc. Launches New HiFi Sequencing Workflow

Revenue beats expectations

Full year 2020 earnings released: EPS US$0.18 (vs US$0.55 loss in FY 2019)